Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allylix secures $6 mil. in venture capital

This article was originally published in The Tan Sheet

Executive Summary

The San Diego, Calif.-based biotech firm raises $6 million in series C financing to commercialize the compound nootkatone and other products for flavor and fragrance applications. Nootkatone, produced from grapefruit peel extractions, is a citrus flavor used in fruit juices and sodas. The funding validates Allylix's technology platform - which "enables low-cost production of high-value terpene products through yeast fermentation" - and commercial viability, giving the firm a chance to deliver its products to the market, says CEO Carolyn Fritz. With the funding, Allylix says it plans to create a lower-priced production process and expand applications of nootkatone to more food and fragrance products. Allylix expects another round of series C financing to end in 60 days, according to a release
Advertisement

Related Content

P&G Teams With Amyris To Turn Microbes Into Functional Ingredient "Factories"
Advertisement
UsernamePublicRestriction

Register

PS103789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel